These advantages extend to improvements in insulin sensitivity and glucose uptake, enabling the optimization of type 2 diabetes mellitus management, with reductions in OAD requirements in some of those patients treated with baricitinib. This evidence concerns the gene INS and type 2 diabetes mellitus.